Ladenburg Thalmann Maintains Buy on BrainsWay, Raises Price Target to $18.8
Ladenburg Thalmann analyst Jeffrey Cohen maintains BrainsWay (NASDAQ:BWAY) with a Buy and raises the price target from $18 to $18.8.
Read original at benzingaStocks · News reference
BrainsWay Says Secondary Analysis Of Deep TMS Trial Published In Journal Of Affective Disorders Showed Suicidal Ideation Fell From 22.5% Of 89 Patients At Baseline To 6.7% At Six Weeks
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 27, 2026, 11:30 AM
- Checked
- Aug 27, 2026, 11:30 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
BrainsWay shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY26 sales guidance above analyst estimates.
Read original at benzingaBTIG Maintains Buy on BrainsWay, Raises Price Target to $20
BTIG analyst Sam Eiber maintains BrainsWay (NASDAQ:BWAY) with a Buy and raises the price target from $18 to $20.
Read original at benzinga